Antigenic Essence: Upgrade of Cellular Cancer Vaccines.
SANTAVAC
antiangiogenic vaccine
antigenic essence
cancer vaccine
endothelial cells
mass spectrometry
preventive vaccine
proteomic footprint
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
12 Feb 2021
12 Feb 2021
Historique:
received:
06
01
2021
accepted:
10
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
7
3
2021
Statut:
epublish
Résumé
The development of anticancer immunotherapy is characterized by several approaches, the most recognized of which include cellular vaccines, tumor-associated antigens (TAAs), neoantigens, and chimeric antigen receptor T cells (CAR-T). This paper presents antigenic essence technology as an effective means for the production of new antigen compositions for anticancer vaccination. This technology is developed via proteomics, cell culture technology, and immunological assays. In terms of vaccine development, it does not fit into any of the above-noted approaches and can be considered a new direction. Here we review the development of this technology, its main characteristics, comparison with existing approaches, and the features that distinguish it as a novel approach to anticancer vaccination. This review will also highlight the benefits of this technology over other approaches, such as the ability to control composition, optimize immunogenicity and similarity to target cells, and evade major histocompatibility complex restriction. The first antigenic essence products, presented under the SANTAVAC brand, are also described.
Identifiants
pubmed: 33673325
pii: cancers13040774
doi: 10.3390/cancers13040774
pmc: PMC7917603
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Immunol Methods. 1987 Jun 26;100(1-2):83-90
pubmed: 3298442
Clin Chem. 2016 Jan;62(1):48-69
pubmed: 26719571
Clin Cancer Res. 2012 Feb 1;18(3):882-9
pubmed: 22156611
Science. 1989 May 12;244(4905):707-12
pubmed: 2470152
Chem Rev. 2020 Mar 25;120(6):3210-3229
pubmed: 31804810
J Immunol. 1997 Feb 15;158(4):1796-802
pubmed: 9029118
Nature. 1997 Nov 27;390(6658):404-7
pubmed: 9389480
Nat Med. 2000 Oct;6(10):1160-6
pubmed: 11017149
Eur J Cancer. 1993;29A(15):2158-60
pubmed: 8297657
Semin Cancer Biol. 1995 Dec;6(6):329-36
pubmed: 8938271
Nat Immunol. 2002 Nov;3(11):999-1005
pubmed: 12407407
Hum Vaccin Immunother. 2013 Jan;9(1):198-209
pubmed: 23442592
Mol Immunol. 2009 Sep;46(15):2931-7
pubmed: 19615748
J Urol. 2002 May;167(5):1995-2000
pubmed: 11956426
Oncogene. 2007 Oct 4;26(45):6469-87
pubmed: 17471238
J Immunother. 2008 Jan;31(1):72-80
pubmed: 18157014
J Biomed Sci. 2010 May 11;17:36
pubmed: 20459778
Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):432-6
pubmed: 7831305
Annu Rev Immunol. 1983;1:273-306
pubmed: 6085785
J Clin Oncol. 1990 Nov;8(11):1858-67
pubmed: 2230873
J Immunother Cancer. 2015 Nov 17;3:48
pubmed: 26579225
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18769-76
pubmed: 20974924
J Immunol Res. 2016;2016:5031529
pubmed: 27781211
Clin Cancer Res. 1996 Jan;2(1):21-8
pubmed: 9816085
J Clin Oncol. 2000 Jan;18(1):148-57
pubmed: 10623705
Hepatogastroenterology. 2002 May-Jun;49(45):691-3
pubmed: 12063971
Int J Cancer. 1999 Nov 12;83(4):555-63
pubmed: 10508494
Biomed Pept Proteins Nucleic Acids. 1995;1(3):177-84
pubmed: 9346850
Semin Oncol. 2012 Jun;39(3):276-86
pubmed: 22595050
Mol Cell Proteomics. 2012 Feb;11(2):M111.014480
pubmed: 22074704
Vaccine. 2001 Mar 21;19(17-19):2576-82
pubmed: 11257395
J Exp Med. 1995 Jun 1;181(6):2109-17
pubmed: 7539040
Clin Cancer Res. 2006 Oct 1;12(19):5834-40
pubmed: 17020991
Cancer Sci. 2004 Jan;95(1):85-90
pubmed: 14720332
Science. 1993 May 14;260(5110):937-44
pubmed: 8493532
J Thorac Cardiovasc Surg. 1973 Aug;66(2):320-8
pubmed: 4352772
Mol Cell Proteomics. 2015 Dec;14(12):3105-17
pubmed: 26628741
Rapid Commun Mass Spectrom. 2009 Mar;23(5):680-2
pubmed: 19184978
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Nature. 2000 Jan 27;403(6768):356
pubmed: 10667765
J Intern Med. 2016 Jun;279(6):541-62
pubmed: 26748421
Int J Mol Sci. 2017 Jun 30;18(7):
pubmed: 28665313
Cytotechnology. 2006 Jun;51(2):45-50
pubmed: 19002894
Hum Immunol. 2000 Dec;61(12):1332-8
pubmed: 11163090
Hum Immunol. 1998 Jan;59(1):1-14
pubmed: 9544234
Semin Immunol. 2010 Jun;22(3):132-43
pubmed: 20356763
Immunol Today. 1997 Apr;18(4):175-82
pubmed: 9136454
J Immunother. 2001 May-Jun;24(3):205-11
pubmed: 11394497
Clin Vaccine Immunol. 2011 Jan;18(1):23-34
pubmed: 21048000
Cancer. 2008 Sep 1;113(5):975-84
pubmed: 18646045
Nat Biotechnol. 2002 Jul;20(7):682-8
pubmed: 12089552
Biochim Biophys Acta. 1976 Apr 5;426(4):630-7
pubmed: 1259987
Cancer. 1978 Dec;42(6):2613-25
pubmed: 728864
NPJ Vaccines. 2019 Feb 8;4:7
pubmed: 30774998
Trends Immunol. 2015 Aug;36(8):494-502
pubmed: 26169254
J Transl Med. 2007 Sep 14;5:43
pubmed: 17868452
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Nat Rev Cancer. 2014 Feb;14(2):135-46
pubmed: 24457417
J Biol Chem. 1994 Mar 4;269(9):6689-94
pubmed: 8120026
Mol Immunol. 1994 Dec;31(18):1423-30
pubmed: 7823968
Int J Clin Lab Res. 1997;27(2):81-6
pubmed: 9266277
Hum Vaccin Immunother. 2012 Sep;8(9):1335-53
pubmed: 22894970
Hum Vaccin Immunother. 2015;11(3):689-98
pubmed: 25714389
Eur J Cancer. 2008 Feb;44(3):383-90
pubmed: 18060766
J Cancer. 2010 Nov 29;1:230-41
pubmed: 21151581
J Natl Cancer Inst. 2004 Feb 18;96(4):326-31
pubmed: 14970281
Vaccines (Basel). 2019 Nov 17;7(4):
pubmed: 31744189
Annu Rev Immunol. 1994;12:735-73
pubmed: 8011296
Cancer Immunol Immunother. 2007 Jan;56(1):88-94
pubmed: 16622680
Int J Cancer. 1994 Mar 15;56(6):826-9
pubmed: 8119772
Exp Cell Res. 1961 Dec;25:585-621
pubmed: 13905658
Cytometry. 1997 Jan 1;27(1):77-83
pubmed: 9000588
Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2105-9
pubmed: 7510885
Mol Biother. 1988;1(1):30-6
pubmed: 2855788
Cancer Res. 1979 Aug;39(8):3276
pubmed: 455310
Science. 1994 Apr 29;264(5159):716-9
pubmed: 7513441
J Pharm Pharm Sci. 2007;10(2):144-52
pubmed: 17706173